GlassScriptPhysician profile
Julio A Batista
NPI 1033150321
$3,052.46
in general payments reported to CMS, 2019-2025
14 companies · $437 in 2025
The $437 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $380 · 2021: $538 · 2022: $125 · 2023: $154 · 2024: $639 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $961 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $960.76 |
| Education | $268.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,348.88 | 2019-2023 | Lo Loestrin Fe |
| Astellas Pharma US INC | $671.75 | 2024-2025 | Veozah |
| Exeltis, USA INC. | $312.57 | 2022-2025 | Slynd, Tyblume, Nuvessa |
| Becton, Dickinson and Company | $172.66 | 2023-2025 | Bd Onclarity, Bd Veritor Plus Analyzer |
| Lupin INC. | $145.63 | 2019-2021 | |
| Millicent US INC | $86.45 | 2020-2025 | Intrarosa, Femring |
| Medtronic, INC. | $80.99 | 2021-2023 | Sonicision |
| Avion Pharmaceuticals | $73.94 | 2019-2021 | |
| Evofem Biosciences, INC. | $53.01 | 2024-2025 | Phexxi, Solosec, Phexx |
| Pfizer INC. | $48.56 | 2021 | |
| Duchesnay USA Incorporated | $27.78 | 2019 | |
| Ascend Therapeutics US, LLC | $16.50 | 2019 | |
| Mission Pharmacal Company | $13.74 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julio Batista listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.